Anzeige
Meldung des Tages: Verdoppelt – und noch nicht am Ziel? Dieser Rohstoff-Explorer profitiert vom Antimon-Boom

Ideaya Bioscience News

Aktie
WKN:  A2PJPB ISIN:  US45166A1025 US-Symbol:  IDYA Branche:  Biotechnologie Land:  USA
35,06 $
+1,89 $
+5,70%
30,159 € 09.03.26
Depot/Watchlist
Marktkapitalisierung *
2,62 Mrd. €
Streubesitz
-
KGV
-28,46
Nachhaltigkeits-Score
22 %
Index-Zuordnung
-

Ideaya Bioscience News

15.10.25 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-​Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire
26.09.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08.09.25 - PR Newswire
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market PR Newswire
08.09.25 - PR Newswire
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market PR Newswire
08.09.25 - PR Newswire
IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-​in-class MAT2A inhibitor, and Trodelvy® in MTAP-​Deletion Urothelial ...
08.09.25 - PR Newswire
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma PR Newswire
07.09.25 - PR Newswire
IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer
IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-​in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the ...
04.09.25 - PR Newswire
IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer
IDEAYA Biosciences Announces First-​Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-​in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-​Deletion Non-Small ...
03.09.25 - PR Newswire
IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors
IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-​In-Class PRMT5 Inhibitor for MTAP-​Deletion Solid Tumors PR Newswire
02.09.25 - PR Newswire
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide PR Newswire
29.08.25 - PR Newswire
IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society ...
29.08.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
25.08.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events PR Newswire
18.08.25 - PR Newswire
IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025
IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025 PR Newswire
05.08.25 - PR Newswire
IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update PR Newswire
01.08.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
24.07.25 - PR Newswire
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma PR Newswire
23.07.25 - PR Newswire
IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy PR Newswire
22.07.25 - PR Newswire
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-​in-Class ...
21.07.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event PR Newswire

Newssuche

Videos

newspaper
04.03.26 -6,24%
ROHÖL mit Ziel MINUS 40$?!?
Fundierte Strategien für den Handel der wichtigen News in einem Seminarpaket, plus transparenter ... Mehr »